LUXEMBOURG
CERVICAL CANCER PROFILE

Morbidity and Mortality

Crude cervical cancer incidence per 100 000 women (2020): 7.8
Age-standardized cervical cancer incidence per 100 000 women (2020): 5.2
Cumulative risk of cervical cancer, ages 0-74 (2020): 0.5%
Cervical cancer deaths (2019): 10
Cervical cancer mortality-to-incidence ratio (2020): 0.42
Population-based cancer registry exists (2021): Yes

Primary Prevention

HPV vaccination programme coverage among girls (2020)

<table>
<thead>
<tr>
<th>Programme coverage</th>
<th>0%</th>
<th>20%</th>
<th>40%</th>
<th>60%</th>
<th>80%</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage by age 15 t</td>
<td>no data</td>
<td>43%</td>
<td>63%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Among girls turning 15 years old in 2020, 4 in 10 received their final HPV vaccination dose

HPV vaccination programme (2020):

HPV included in national vaccination programme: Yes
Scale of vaccination programme: National
Year of introduction: 2008
Primary target cohort: 9-13 years

Related risk factors:

Tobacco use prevalence, women aged 15+ years (2020)**: 19%
Condom use at last high-risk sex (-): ND
HIV incidence per 1000, women aged 15+ years (2020): ND

Secondary Prevention

National screening programme for cervical cancer exists (2021): Yes
Primary screening test used (2021): cytology
Target age range of programme (2021): 25-69 years
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): No
Clearly defined referral system exists from primary care to secondary and tertiary care (2021): No

Screening for cervical cancer (2019)

<table>
<thead>
<tr>
<th>Ever screened</th>
<th>0%</th>
<th>20%</th>
<th>40%</th>
<th>60%</th>
<th>80%</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of women aged 30 - 49 years</td>
<td>8%</td>
<td>31%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8 in 10 women have been screened for cervical cancer in the last 5 years

Treatment and Supportive Care

National guidelines on cervical cancer management exist (2021): Yes

Number of radiotherapy units per 10 000 cancer patients (2017): 12
Number of brachytherapy units per 10 000 cancer patients (2017): 6

Cancer diagnosis and treatment services generally available (2021):

Cancer centre or cancer department at tertiary level: Yes
Pathology services (laboratories): Yes
Cancer surgery: Yes
Chemotherapy: Yes
Radiotherapy: Yes

Palliative care for patients with NCDs in the public health system generally available (2021):

In primary health care facilities: Yes
In community or home-based care: Yes

Number of medical staff (per 10 000 cancer patients):

Radiation oncologists (2019): 18
Medical physicists (2019): ND
Surgeons (2014): 890
Radiologists (2019): 260
Nuclear medicine physicians (2019): 43

Palliative care for patients with NCDs in the public health system generally available (2021):

In primary health care facilities: Yes
In community or home-based care: Yes

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15
70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
90% of women identified with cervical disease receive treatment

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions.

World Health Organization - Cervical Cancer Country Profiles, 2021